Xenon Pharmaceuticals
company in Burnaby, Canada
XENE Nasdaq
ISIN CA98420N1050 SEC CIK 1582313 LEI 549300XV44Q9Z1MIPQ03
Follow Xenon Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$110.4M
−21.5% vs same quarter last year
EPS, diluted
−$1.11
+3.5% vs same quarter last year
Operating cash flow
−$90.3M
−25.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $7.5M | −$345.9M |
| FY24 | $0 | −$234.3M |
| FY23 | $0 | −$182.4M |
| FY22 | $9.4M | −$125.4M |
| FY21 | $18.4M | −$78.9M |
| FY20 | $32.2M | −$28.8M |
| FY19 | $6.8M | −$41.6M |
| FY18 | - | −$34.5M |
| FY17 | $311K | −$30.7M |
| FY16 | $1.8M | −$23M |
| FY15 | $15.6M | −$15.8M |
| FY14 | $28.4M | $13M |
| FY13 | $27.4M | $12M |
| FY12 | $14.3M | −$4.3M |
| FY11 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −4974.3% | −4612.1% |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | −1368.9% | −1328.9% |
| FY21 | −428.4% | −427.8% |
| FY20 | −97.3% | −89.7% |
| FY19 | −627% | −609.1% |
| FY18 | - | - |
| FY17 | −10474.3% | −9872.7% |
| FY16 | −1376.4% | −1275.5% |
| FY15 | −60.1% | −101.1% |
| FY14 | 39.1% | 45.9% |
| FY13 | 35.5% | 44% |
| FY12 | −22% | −30.1% |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$279.9M |
| FY24 | −$184.5M |
| FY23 | −$156.7M |
| FY22 | −$103.9M |
| FY21 | −$71.6M |
| FY20 | −$50.8M |
| FY19 | −$6M |
| FY18 | −$35.2M |
| FY17 | −$29M |
| FY16 | −$19.8M |
| FY15 | −$18.7M |
| FY14 | −$1.3M |
| FY13 | −$3.5M |
| FY12 | $45M |
| FY11 | - |
- Xenon Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Xenon Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −4612.1% | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | −1328.9% | −80.4% |
| FY21 | −427.8% | −71.9% |
| FY20 | −89.7% | −62.2% |
| FY19 | −609.1% | −46.3% |
| FY18 | - | −49.6% |
| FY17 | −9872.7% | −45.9% |
| FY16 | −1275.5% | −36% |
| FY15 | −101.1% | −38.4% |
| FY14 | 45.9% | −35.5% |
| FY13 | 44% | −37.1% |
| FY12 | −30.1% | −29.1% |
| FY11 | - | −27.9% |